Top Tech Companies in Raleigh, NC (1,146)

Strong Revenue Growth: Global revenue increased to $60.2B in FY2026, with growth accelerating versus the prior year and all major service lines expanding. Asia Pacific and the Americas contributed most, though expansion was not uniform across regions.

Innovation-Driven Growth: Significant, multi‑billion investments are scaling AI and technology capabilities, alongside large‑scale AI upskilling across the workforce. Initiatives such as AI‑native assurance tools and the PwC One platform indicate a push to embed tech-enabled delivery.

Product Line Growth: New and expanded offerings in technology, consulting, strategy, and tax are being built through acquisitions and strategic investments. Within the latest year, Tax and Legal led growth, with Advisory and Assurance also advancing.

Strong Revenue Growth: Revenue is rising at a low-double-digit pace, with FY 2025 up 14% and Q1–Q2 2026 growing 15% and 13% year over year. Evidence indicates this marked a second consecutive year of double-digit annual growth with continued momentum into 2026.

Profitability: Profitability expanded faster than sales in 2025, with adjusted EBITDA up 25% and GAAP net income from continuing operations up 53%. This pattern points to improved operating leverage, even as quarterly results vary.

Market Expansion: International and dealer-network metrics show expansion, with total paying dealers up about 5% and international dealers up 11% year over year; international revenue rose 28% in Q2 2026. These gains suggest growth beyond the U.S. base and higher monetization per dealer.

Investor Backing & Capital Strength: Evidence indicates a $50 million Series D in April 2026 led by Boehringer Ingelheim, following a Series C in March 2025. This ongoing capital access, including dedicated commercialization funding, signals strong financial support for the next phase of growth.

Strategic Partnerships: Evidence indicates deep relationships with Boehringer Ingelheim and Otsuka, alongside new collaborations such as Ultrahuman for migraine-related technology. These alliances are described as enabling development, regulatory progress, and commercialization pathways across multiple programs.

Product Line Growth: Evidence indicates multiple FDA milestones—Rejoyn for major depressive disorder symptoms (2024), CT-132 for episodic migraine prevention (2025), and Motivista/CT-155 for negative symptoms of schizophrenia (2026)—plus expansion into obesity and cardiometabolic disease via acquired assets. These developments broaden the portfolio across therapeutic areas and advance late-stage candidates toward market.

Strong Revenue Growth: Revenue is rising across 2025 and into 2026, with Galleri driving year-over-year increases and volumes outpacing revenue. Feedback suggests growth accelerated in early 2026 as test adoption broadened.

Strategic Partnerships: Partnerships such as Epic EHR integration and a collaboration with Samsung for Asia expansion are expanding distribution and market access. These relationships also support commercialization through employers, health systems and digital-health channels.

Investor Backing & Capital Strength: A sizable cash balance and recent equity financing provide a substantial runway to fund R&D and commercial expansion. This capital position helps buffer the costs of scaling while regulatory review proceeds.

Strong Market Position & Advantage: Celonis is repeatedly characterized as the dominant pioneer and market leader in process mining and process intelligence, with sustained recognition from Gartner, Forrester, and Everest and visibility in rankings like the Fortune Future 50 and Forbes Cloud 100. This position is reinforced by a substantial enterprise footprint, including thousands of deployments across more than 20 global locations.

Innovation-Driven Growth: The company is extending beyond traditional dashboards into operational AI, launching its Context Model, adding AI copilots, and agreeing to acquire Ikigai Labs to bolster decision intelligence. These moves signal an evolution toward automated execution and higher platform stickiness among large enterprises.

Strategic Partnerships: Integrations and collaborations with Microsoft, Oracle, AWS, and Databricks embed Celonis within major enterprise data and AI ecosystems. This ecosystem presence expands distribution paths and strengthens its role as an operational context layer for enterprise AI.

Strong Revenue Growth: Revenue increased from $2.678B in 2023 to $3.053B in 2025 and continued to rise 5.2% year over year in Q2 2026, with organic growth of 6.6%.

Profitability: Adjusted EBITDA rose 20.7% in 2025 to $792M and grew 11.2% in Q2 2026, with margin expansion to about 26.8% alongside higher adjusted net income.

Market Expansion: The company is expanding its footprint through acquisitions and capacity investments, including completing the Eurofins Electrical & Electronics business in October 2026 and enlarging testing facilities.

Strong Revenue Growth: Historical 2022 results showed robust year-over-year expansion, and leadership later indicated the business was heading toward about $2 billion in revenue. These signals indicate meaningful scale and ongoing momentum.

Innovation-Driven Growth: AI product adoption and platform usage have surged since 2023, with a sizable share of customers upgrading to new AI capabilities. Company disclosures describe sharp increases in monthly active AI users and total interactions analyzed on the platform.

Market Expansion: Completion of the $6.75B Press Ganey Forsta acquisition broadens reach into healthcare experience data, relationships, and analytics. This materially expands the company’s footprint and opportunities for cross-sell.

Profitability: Operating earnings and margins improved notably in 2026, with Q3 operating earnings up sharply year over year and the operating margin rising to 5.6%. Feedback suggests earnings resilience is being supported by operational changes and a shifting business mix.

Strong Revenue Growth: Reported annual revenue expanded from $226.6B in 2023 to $270.6B in 2025, including roughly 12% growth in 2024 and 7% in 2025. This establishes a robust multi‑year revenue trajectory even as recent growth rates have moderated.

Cost & Operational Efficiency: Cost controls and operational improvements are described as lifting earnings despite lower revenue in 2026. Optum Health’s operating earnings rose from $41M to $735M year over year while serving fewer value‑based patients, indicating stronger execution.

Strong Revenue Growth: Reported three-year revenue growth of 1,012% and an Inc. 5000 rank of No. 336 indicate rapid scaling, and revenue was said to have doubled in both 2023 and 2024. Together these signals point to sustained top-line momentum.

Investor Backing & Capital Strength: A $127 million Series C at a reported $1 billion valuation and total funding exceeding $250 million signal substantial capital availability. This backing supports continued product development and go-to-market investment.

Market Expansion: New hubs in Raleigh and Toronto, government-confirmed plans for roughly 291 Raleigh jobs, and rising third‑party headcount estimates point to active geographic and organizational growth. Expanding offices and staffing suggest deeper North American coverage.

Strategic Partnerships: Partnerships with VMware (including Pinnacle status and Cloud Foundation as a Service Partner of the Year), the AHEAD alignment, and the Ascend Partner Program are being used to scale joint capabilities and channel-driven growth. These ecosystem moves broaden go-to-market reach across multi-cloud, security, and modernization opportunities.

Market Expansion: Physical presence expanded with a major Raleigh build-out and a second office to support rising demand and operational capacity. Operating scale is further evidenced by thousands of managed-cloud customers and extensive public-cloud migrations.

Investor Backing & Capital Strength: As a Cox Business subsidiary, the company benefits from parent-company resources that underpin continued scaling of cloud, AI, and cybersecurity portfolios. This corporate support is positioned as providing robust financial stability.

Strong Revenue Growth: Revenue is described as having doubled between 2019 and 2022, with consecutive Inc. 5000 placements in 2023 and 2024 reinforcing a multi-year expansion trajectory. As a result, growth appears to be more than a one-off spike across that period.

Investor Backing & Capital Strength: Growth-capital from Boathouse Capital in February 2025 is presented as financing to scale services, enter new markets, and pursue targeted expansion. This capital support signals external confidence in the next stage of the company’s growth.

Market Expansion: Operations have extended beyond the U.S. to London and Bulgaria, the Chicago headquarters footprint has increased, and the Mashey acquisition broadened capabilities and reach. These moves indicate increasing geographic capacity and service delivery scale.

Strong Market Position & Advantage: Top-tier ENR specialty rankings (#3 wind, #5 solar, #6 storage), a rising overall Top 500 position, and regional Design Firm of the Year recognition indicate a strong competitive position in renewables and power delivery. These repeated placements and awards suggest leadership in high-growth segments across multiple regions.

Strong Revenue Growth: A sustained climb on ENR’s Top 500 list, alongside reports of higher revenue and expanding headcount, signals robust topline momentum. Recognition on growth-focused industry lists further reinforces this trajectory.

Investor Backing & Capital Strength: A majority investment by Blackstone Energy Transition Partners and additional funding provide substantial capital to scale in renewables, grid, and infrastructure markets. Management’s continued stake and stated plans to leverage this backing suggest ample resources for both organic expansion and M&A.

Investor Backing & Capital Strength: Recent $300M financing in March 2026, conversion to a C‑corp, and Alphabet remaining a significant minority investor indicate strong capital access to scale its AI‑native precision health platform. Earlier large rounds and ongoing backing provide resources for expansion while pursuing independence.

Product Line Growth: The company has expanded offerings with the AI‑native Pre platform (including opening Exchange and Workbench self‑serve/free tiers), the Verily Me app, and the Lightpath Metabolic program positioned for broad availability in 2026. These launches and migrations from Onduo signal a cohesive product strategy aimed at broader adoption.

Strategic Partnerships: Partnerships with NVIDIA, Samsung, UCHealth/CU Anschutz, and NIH “All of Us” via Vanderbilt, plus CMS ACCESS model participation, point to growing ecosystem traction. These collaborations expand research and care use cases and distribution channels.

Strong Revenue Growth: Revenue is reported at $763 million, and feedback suggests year-over-year increases alongside expanding project volume and major federal contracts.

Strong Market Position & Advantage: Consistent top-tier placements on ENR lists and recognition across specialized sectors indicate a durable competitive stance in U.S. engineering and consulting markets.

Leadership Stability: A restructured executive framework and appointment of a new CEO are framed as measures to guide scaling operations and sustain the growth trajectory.